Overview

A blood-based PD-L1 gene-expression assay using fluorescence quantitative PCR brings immune-biomarker testing to patients who cannot give tissue. Its regulatory story is about validation for a liquid format: the method must prove it tracks tissue PD-L1 closely enough to guide care. For distributors, the key procurement question is whether the lab holds a validation that compares blood results against matched IHC on the same patient. A liquid result only earns a place in care when it has been shown to agree with tissue on enough cases to trust the threshold.

How It Works

Whole blood RNA is extracted, reverse-transcribed, and amplified by fluorescence PCR across PD-L1 transcript targets with an internal reference. Cycle-threshold values are converted to a relative expression level. Because no staining is involved, scoring is instrument-driven and reproducible, which simplifies cross-site and cross-border consistency. An extraction control confirms RNA quality before amplification, blocking samples that would give a misleading low signal.

Clinical Indications

It is indicated when tissue is unavailable or when a repeat PD-L1 read is needed without another biopsy. Oncology teams use it as a complementary signal alongside imaging and prior IHC. Programs also use it to track expression over time, since a blood draw is far easier to repeat than a re-biopsy.

Specimen & Turnaround

A two to three mL EDTA blood tube is required; hemolysis is avoided at draw. The report gives a relative expression value with the PCR method named, and notes the liquid-biopsy context. Turnaround is short because the workflow has few manual steps, which suits a result that informs a near-term therapy talk.

Storage & Logistics

Blood ships refrigerated with cold pack; RNA stability is protected by prompt processing. Service labs document the validated PCR run so overseas partners meet the same quality benchmark. Lot-controlled reagents and a recorded amplification curve give auditors the traceability a regulated liquid biopsy expects. Pre-paid courier labels keep the cold chain unbroken from draw to lab, which protects the RNA on long international routes.

FAQ

Q: Why use blood PCR instead of tissue IHC? A: It reaches patients without a biopsy and gives an instrument-based, reproducible score. Repeated draws are easy, so expression can be tracked over time.

Q: Does it replace 22C3 IHC? A: No, it is complementary and reported in the liquid-biopsy context. The blood value should be read alongside, not instead of, the tissue history.

Q: How is the sample kept stable? A: EDTA blood refrigerated with cold pack, processed promptly to protect RNA. Avoid hemolysis at draw, since broken cells can skew the expression read.